Clinical Trial Update: A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Ridinilazole to Fidaxomicin for treating Clostridioides difficile infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• Fidaxomicin (fidaxomicin)
• Ridinilazole (ridinilazole)

Snippet

Sponsor: Summit Therapeutics | Conditions: Clostridium Difficile Infection | Phase 2 | Status: COMPLETED